Editas Medicine Inc
Closed
SectorHealthcare
3.64 11.66
Overview
Share price change
24h
Min
3.61
Max
3.64
Income | -19M -25M |
|---|---|
Sales | -22M 2.8M |
EPS | -0.26 |
Profit margin | -882.444 |
Employees | 87 |
EBITDA | -18M -23M |
Recommendations | Buy |
|---|---|
12 Months Forecast | +97.26% upside |
Next Earnings | 10 Aug 2026 |
|---|
Market Cap | 173M 467M |
|---|---|
Previous open | -8.02 |
Previous close | 3.64 |
Editas Medicine Inc Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
Editas Medicine Inc Forecast
Price Target
By TipRanks
97.26% upside
12 Months Forecast
Average 7.2 USD 97.26%
High 15 USD
Low 4 USD
Based on 7 Wall Street analysts offering 12 month price targets forEditas Medicine Inc - Dist in the last 3 months.
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About Editas Medicine Inc
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing alpha-beta T cells for solid and liquid tumors; and gamma delta T cell therapies to treat cancer. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; collaboration and nonexclusive license agreement with Genevant Sciences to develop Novel mRNA-LNP gene editing therapeuticsand strategic alliance and option agreement with Allergan Pharmaceuticals International Limited, as well as collaboration with Bristol Myers Squibb for research and development of alpha-beta T cell medicines for the treatment of cancer and autoimmune diseases. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.